Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases

Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date

(2018) Kentaro Sugano   Therapeutic Advances in Gastroenterology

KFP-H008 blocks gastric acid secretion through inhibiting H + -K + -ATPase

(2017) Cheng-yuan Li et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Pharmacokinetics, Pharmacodynamics and Tolerability of DWP14012, A Novel Acid Pump Antagonist, in Healthy Subjects

(2017) Jaeseong Oh et al.   GASTROENTEROLOGY

Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study

(2017) Takashi Kawai et al.   GUT

Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study

(2017) Yuji Mizokami et al.   GUT

Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori : A multicenter, prospective, randomized trial

(2017) Soichiro Sue et al.   HELICOBACTER

Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection

(2017) Toshihiro Nishizawa et al.   JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION

Magnitude and direction of the association between Clostridium difficile infection and proton pump inhibitors in adults and pediatric patients: a systematic review and meta-analysis

(2017) Tadayuki Oshima et al.   JOURNAL OF GASTROENTEROLOGY

Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth

(2017) Tingting Su et al.   JOURNAL OF GASTROENTEROLOGY

Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility

(2017) Nobuyuki Takahashi et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection

(2017) Maria Teresa Mascellino et al.   Drug Design Development and Therapy

Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-LineHelicobacter pyloriEradication: A Randomized Controlled Trial

(2017) Masafumi Maruyama et al.   Canadian Journal of Gastroenterology and Hepatology

Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438)

(2016) Kazuyoshi Otake et al.   ADVANCES IN THERAPY

Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study

(2016) Yuuichi Sakurai et al.   ADVANCES IN THERAPY

Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials

(2016) H. Miwa et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype

(2016) T. Kagami et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men

(2016) Yuuichi Sakurai et al.   CLINICAL DRUG INVESTIGATION

Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study

(2016) Helen Jenkins et al.   CLINICAL DRUG INVESTIGATION

Successful eradication of Helicobacter pylori infection with vonoprazan-based triple therapy after failure of PPI-based triple therapy

(2016) Kousaku Kawashima et al.   DIGESTIVE AND LIVER DISEASE

Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa

(2016) Jun Matsukawa et al.   DIGESTIVE DISEASES AND SCIENCES

Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance

(2016) Hiroshi Matsumoto et al.   DIGESTIVE DISEASES AND SCIENCES

Efficacy of vonoprazan-based second-line Helicobacter pylori eradication therapy in patients for whom vonoprazan-based first-line treatment failed

(2016) Yasumi Katayama et al.   GUT

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

(2016) Kazunari Murakami et al.   GUT

Influence of potassium-competitive acid blocker on the gut microbiome ofHelicobacter pylori-negative healthy individuals

(2016) Taketo Otsuka et al.   GUT

Evidence-based clinical practice guidelines for peptic ulcer disease 2015

(2016) Kiichi Satoh et al.   JOURNAL OF GASTROENTEROLOGY

Gastrointestinal mucosal barrier function and diseases

(2016) Tadayuki Oshima et al.   JOURNAL OF GASTROENTEROLOGY

Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015

(2016) Katsuhiko Iwakiri et al.   JOURNAL OF GASTROENTEROLOGY

Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases

(2016) Nobuhiro Inatomi et al.   PHARMACOLOGY & THERAPEUTICS

Medical cost, incidence rate, and treatment status of gastroesophageal reflux disease in Japan: analysis of claims data

(2016) Hiroto Miwa et al.   JOURNAL OF MEDICAL ECONOMICS

Safety and efficacy of Vonoprazan-based triple therapy against Helicobacter pylori infection: A single-center experience with 1118 patients

(2016) Daisuke Fukuda et al.   Therapeutic Advances in Gastroenterology

The binding selectivity of vonoprazan (TAK-438) to the gastric H+,K+-ATPase

(2015) D. R. Scott et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

(2015) H. Jenkins et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Letter: promising results ofHelicobacter pylorieradication with vonoprazan-based triple therapy after failure of proton pump inhibitor-based triple therapy

(2015) T. Inaba et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis

(2015) K. Ashida et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label cross-over study

(2015) Y. Sakurai et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis

(2015) K. Ashida et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations

(2015) Hirotoshi Echizen   CLINICAL PHARMACOKINETICS

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

(2015) Yuuichi Sakurai et al.   Clinical and Translational Gastroenterology

Epithelial-derived nuclear IL-33 aggravates inflammation in the pathogenesis of reflux esophagitis

(2014) Jing Shan et al.   JOURNAL OF GASTROENTEROLOGY

A Randomized, Comparative Trial of a Potassium-Competitive Acid Blocker (AZD0865) and Esomeprazole for the Treatment of Patients With Nonerosive Reflux Disease

(2013) John Dent et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs

(2013) Kentaro Sugano et al.   BMC GASTROENTEROLOGY

Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review

(2013) Hashem B El-Serag et al.   GUT

Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan

(2013) Kazunari Murakami et al.   JOURNAL OF GASTROENTEROLOGY

Gastroesophageal reflux disease: Update on inflammation and symptom perception

(2013) Annamaria Altomare   WORLD JOURNAL OF GASTROENTEROLOGY

The Costs and Consequences of Adequately Managed Chronic Non-Cancer Pain and Chronic Neuropathic Pain

(2013) R. Andrew et al.   Pain Practice

Nonsteroidal Anti-Inflammatory Drugs, Gastroprotection, and Benefit-Risk

(2013) Robert Andrew Moore et al.   Pain Practice

Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors

(2013) Jai Moo Shin et al.   Journal of Neurogastroenterology and Motility

Randomised clinical trial: esomeprazole for the prevention of nonsteroidal anti-inflammatory drug-related peptic ulcers in Japanese patients

(2012) K. Sugano et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy of Twice-Daily Rabeprazole for Reflux Esophagitis Patients Refractory to Standard Once-Daily Administration of PPI: The Japan-Based TWICE Study

(2012) Yoshikazu Kinoshita et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Reported Side Effects and Complications of Long-term Proton Pump Inhibitor Use: Dissecting the Evidence

(2012) David A. Johnson et al.   Clinical Gastroenterology and Hepatology

Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial

(2012) Kentaro Sugano et al.   JOURNAL OF GASTROENTEROLOGY

Discovery of a Novel Pyrrole Derivative 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Fumarate (TAK-438) as a Potassium-Competitive Acid Blocker (P-CAB)

(2012) Yasuyoshi Arikawa et al.   JOURNAL OF MEDICINAL CHEMISTRY

Dexlansoprazole MR – A review

(2011) Tiberiu Hershcovici et al.   ANNALS OF MEDICINE

A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands

(2011) Jun Matsukawa et al.   BIOCHEMICAL PHARMACOLOGY

Adverse Effects of Long-Term Proton Pump Inhibitor Therapy

(2011) Edward Sheen et al.   DIGESTIVE DISEASES AND SCIENCES

A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in Animals

(2011) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Patient and Physician Satisfaction with Proton Pump Inhibitors (PPIs): Are There Opportunities for Improvement?

(2010) William D. Chey et al.   DIGESTIVE DISEASES AND SCIENCES

Pharmacologic Aspects of Eradication Therapy for Helicobacter pylori Infection

(2010) Takahisa Furuta et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Nonsteroidal Antiinflammatory Drug-Related Injury to the Gastrointestinal Tract: Clinical Picture, Pathogenesis, and Prevention

(2010) Carmelo Scarpignato et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Helicobacter pylori treatment in the era of increasing antibiotic resistance

(2010) D. Y. Graham et al.   GUT

Clinical trial: Inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects

(2010) Hyung-Keun Kim et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases

(2010) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects

(2009) D. A. PEURA et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials

(2009) Majid Vakily et al.   CURRENT MEDICAL RESEARCH AND OPINION

Validation of a conscious rat model for the discovery of novel agents that inhibit gastric acid secretion

(2008) Colin A. Campbell et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Early Stellate Cell Activation and Veno-occlusive-disease (VOD)–like Hepatotoxicity in Dogs Treated with AR-H047108, an Imidazopyridine Proton Pump Inhibitor

(2008) Anna-Lena Berg et al.   TOXICOLOGIC PATHOLOGY

New concepts of resistance in the treatment of Helicobacter pylori infections

(2008) David Y Graham et al.   Nature clinical practice. Gastroenterology & hepatology